TY - JOUR T1 - Digestive Manifestations in Patients Hospitalized with COVID-19 JF - medRxiv DO - 10.1101/2020.07.07.20143024 SP - 2020.07.07.20143024 AU - B. Joseph Elmunzer AU - Rebecca L. Spitzer AU - Lydia D. Foster AU - Ambreen A. Merchant AU - Eric F. Howard AU - Vaishali A. Patel AU - Mary K. West AU - Emad Qayed AU - Rosemary Nustas AU - Ali Zakaria AU - Marc S. Piper AU - Jason R. Taylor AU - Lujain Jaza AU - Nauzer Forbes AU - Millie Chau AU - Luis F. Lara AU - Georgios I. Papachristou AU - Michael L. Volk AU - Liam G. Hilson AU - Selena Zhou AU - Vladimir M. Kushnir AU - Alexandria M. Lenyo AU - Caroline G. McLeod AU - Sunil Amin AU - Gabriela N. Kuftinec AU - Dhiraj Yadav AU - Charlie Fox AU - Jennifer M. Kolb AU - Swati Pawa AU - Rishi Pawa AU - Andrew Canakis AU - Christopher Huang AU - Laith H. Jamil AU - Andrew M. Aneese AU - Benita K. Glamour AU - Zachary L Smith AU - Katherine A. Hanley AU - Jordan Wood AU - Harsh K. Patel AU - Janak N. Shah AU - Emil Agarunov AU - Amrita Sethi AU - Evan L. Fogel AU - Gail McNulty AU - Abdul Haseeb AU - Judy A. Trieu AU - Rebekah E. Dixon AU - Jeong Yun Yang AU - Robin B. Mendelsohn AU - Delia Calo AU - Olga C. Aroniadis AU - Joseph F. LaComb AU - James M. Scheiman AU - Bryan G. Sauer AU - Duyen T. Dang AU - Cyrus R. Piraka AU - Eric D. Shah AU - Heiko Pohl AU - William M. Tierney AU - Stephanie Mitchell AU - Ashwinee Condon AU - Adrienne Lenhart AU - Kulwinder S. Dua AU - Vikram S. Kanagala AU - Ayesha Kamal AU - Vikesh K. Singh AU - Maria Ines Pinto-Sanchez AU - Joy M. Hutchinson AU - Richard S. Kwon AU - Sheryl J. Korsnes AU - Harminder Singh AU - Zahra Solati AU - Amar R. Deshpande AU - Don C. Rockey AU - Teldon B. Alford AU - Valerie Durkalski AU - the North American Alliance for the Study of Digestive Manifestations of COVID-19 Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/09/2020.07.07.20143024.abstract N2 - Background The prevalence and significance of digestive manifestations in COVID-19 remain uncertain.Methods Consecutive patients hospitalized with COVID-19 were identified across a geographically diverse alliance of medical centers in North America. Data pertaining to baseline characteristics, symptomatology, laboratory assessment, imaging, and endoscopic findings from the time of symptom onset until discharge or death were manually abstracted from electronic health records to characterize the prevalence, spectrum, and severity of digestive manifestations. Regression analyses were performed to evaluate the association between digestive manifestations and severe outcomes related to COVID-19.Results A total of 1992 patients across 36 centers met eligibility criteria and were included. Overall, 53% of patients experienced at least one gastrointestinal symptom at any time during their illness, most commonly diarrhea (34%), nausea (27%), vomiting (16%), and abdominal pain (11%). In 74% of cases, gastrointestinal symptoms were judged to be mild. In total, 35% of patients developed an abnormal alanine aminotransferase or total bilirubin level; these were elevated to less than 5 times the upper limit of normal in 77% of cases. After adjusting for potential confounders, the presence of gastrointestinal symptoms at any time (odds ratio 0.93, 95% confidence interval 0.76-1.15) or liver test abnormalities on admission (odds ratio 1.31, 95% confidence interval 0.80-2.12) were not independently associated with mechanical ventilation or death.Conclusions Among patients hospitalized with COVID-19, gastrointestinal symptoms and liver test abnormalities were common but the majority were mild and their presence was not associated with a more severe clinical course.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis was an observational studyFunding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional review board approval was obtained at each center prior to patient identification and data collection.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll authors had access the data ER -